{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:27:58Z","timestamp":1780399678734,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["CCR18548293"],"award-info":[{"award-number":["CCR18548293"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA248033"],"award-info":[{"award-number":["R01CA248033"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH2010312"],"award-info":[{"award-number":["W81XWH2010312"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH2010332"],"award-info":[{"award-number":["W81XWH2010332"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000969","name":"American Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000983","name":"Mary Kay Foundation","doi-asserted-by":"publisher","award":["07-19"],"award-info":[{"award-number":["07-19"]}],"id":[{"id":"10.13039\/100000983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bbcan.2022.188702","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T16:04:03Z","timestamp":1645805043000},"page":"188702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs"],"prefix":"10.1016","volume":"1877","author":[{"given":"Xuemin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2022.188702_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2022.188702_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41585-020-0359-z","article-title":"Understanding genomics and the immune environment of penile cancer to improve therapy","volume":"17","author":"Aydin","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbcan.2022.188702_bb0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2022.188702_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0030","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","article-title":"Myeloid-derived suppressor cells: a propitious road to clinic","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2022.188702_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.bbcan.2022.188702_bb0040","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2022.188702_bb0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/pros.24213","article-title":"Immunotherapy in treatment of metastatic prostate cancer: an approach to circumvent immunosuppressive tumor microenvironment","volume":"81","author":"Sun","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2022.188702_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188702_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205065","article-title":"Immunotherapies in genitourinary oncology: where are we now? Where are we going?","volume":"13","author":"Jang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2022.188702_bb0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2022.188702_bb0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2022.188702_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw9159","article-title":"Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue","volume":"4","author":"Si","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0085","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188702_bb0090","article-title":"Rational targeting of immunosuppressive neutrophils in cancer","volume":"107556","author":"Zhao","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2022.188702_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and Meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2022.188702_bb0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1186\/s12885-020-07410-2","article-title":"A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment","volume":"20","author":"Kawahara","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2022.188702_bb0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","article-title":"Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis","volume":"23","author":"Guan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bbcan.2022.188702_bb0110","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188702_bb0115","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-14-3145","article-title":"TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients","volume":"21","author":"Hossain","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188702_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cjp2.160","article-title":"Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer","volume":"6","author":"Wen","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2022.188702_bb0135","article-title":"Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model, Biochimica et biophysica acta","volume":"1867","author":"Zhao","year":"2021","journal-title":"Mol. Basis Dis."},{"key":"10.1016\/j.bbcan.2022.188702_bb0140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s43018-021-00227-3","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2022.188702_bb0145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2326-6066.CIR-17-0385","article-title":"Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer","volume":"6","author":"Jachetti","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0150","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijms21072337","article-title":"Differential targeting of Gr-MDSCs, T cells and prostate cancer cells by Dactolisib and Dasatinib","volume":"21","author":"Liu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2022.188702_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2022.188702_bb0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0165","first-page":"385","article-title":"The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma, the journal of pathology","volume":"7","author":"Tessier-Cloutier","year":"2021","journal-title":"Clin. Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0170","doi-asserted-by":"crossref","first-page":"1747731","DOI":"10.1080\/2162402X.2020.1747731","article-title":"The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients","volume":"9","author":"Margaroli","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2022.188702_bb0175","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","article-title":"Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with Intratumoral expression of IL1\u03b2, IL8, CXCL5, and Mip-1\u03b1","volume":"23","author":"Najjar","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","article-title":"Blocking IL1 Beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses","volume":"27","author":"Aggen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0185","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0190","doi-asserted-by":"crossref","first-page":"63290","DOI":"10.18632\/oncotarget.18796","article-title":"HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2022.188702_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.omtm.2018.02.009","article-title":"A non-integrating lentiviral approach overcomes Cas9-induced immune rejection to establish an immunocompetent metastatic renal cancer model, molecular therapy","volume":"9","author":"Hu","year":"2018","journal-title":"Meth. Clin. Dev."},{"key":"10.1016\/j.bbcan.2022.188702_bb0200","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0205","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2022.188702_bb0210","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc3858","article-title":"Modelling bladder cancer in mice: opportunities and challenges","volume":"15","author":"Kobayashi","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188702_bb0220","article-title":"Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2022.188702_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","article-title":"Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer","volume":"479","author":"Takeyama","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2022.188702_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040814","article-title":"Penile cancer-derived cells molecularly characterized as models to guide targeted therapies","volume":"10","author":"Kuasne","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2022.188702_bb0235","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41419-018-0736-1","article-title":"Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines","volume":"9","author":"Zhou","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2022.188702_bb0240","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2020.05.033","article-title":"Establishment, characterization, and imaging of a first platinum-resistant penile cancer patient-derived xenograft in nude mice: a eUROGEN project","volume":"78","author":"Thomas","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0245","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","article-title":"Effective combinatorial immunotherapy for penile squamous cell carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2022.188702_bb0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/path.5475","article-title":"HPV16 induces penile intraepithelial neoplasia and squamous cell carcinoma in transgenic mice: first mouse model for HPV-related penile cancer","volume":"251","author":"Medeiros-Fonseca","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.20892\/j.issn.2095-3941.2019.0372","article-title":"Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment","volume":"17","author":"Zhang","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bbcan.2022.188702_bb0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann. Oncol."},{"issue":"suppl 6S","key":"10.1016\/j.bbcan.2022.188702_bb0265","article-title":"Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies","volume":"36","author":"Nadal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2022.188702_bb0270","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1073\/pnas.1800695115","article-title":"Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers","volume":"115","author":"Feng","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2022.188702_bb0275","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck Cancer models","volume":"26","author":"Greene","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-20-0312","article-title":"Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0285","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/1078-0432.CCR-18-1277","article-title":"STAT3 inhibition combined with CpG Immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers","volume":"24","author":"Moreira","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188702_bb0290","article-title":"Human isogenic cell line models for neutrophils and myeloid-derived suppressor cells","volume":"21","author":"Zhang","year":"2020","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T13:07:33Z","timestamp":1735391253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X22000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0304419X22000270"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188702","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188702"}}